1776 Yorktown
Suite 550
Houston, TX 77056
United States
(832) 260-0222
https://www.nexalin.com
Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 6
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Mark White | President, CEO, CFO & Director | 442,5k | N/A | 1962 |
Dr. David Owens M.D. | Chief Medical Officer & Director | 42,8k | N/A | 1961 |
Mr. Michael Nketiah | Senior Vice-President of Quality, Regulatory & Clinical Affairs | 280k | N/A | 1976 |
Ms. Marilyn Elson | Controller | 382,72k | N/A | 1953 |
Mr. John Patrick Claude | Co-Founder and Director of Engineering & Development | N/A | N/A | N/A |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Nexalin Technology, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.